Home » FDA TO DISCUSS NEW INDICATION FOR EXELON
FDA TO DISCUSS NEW INDICATION FOR EXELON
An FDA advisory panel plans to consider Novartis' Alzheimer's drug Exelon for an additional indication of treatment for mild-to-moderate dementia associated with Parkinson's disease.
The agency's Peripheral and Central Nervous System Drugs Advisory Committee has scheduled a May 17 meeting to discuss the firm's supplemental new drug application for Exelon (rivastigmine tartrate). The drug was approved in April 2000 for the treatment of mild-to-moderate Alzheimer's disease.
For more information, access http://www.fda.gov/oc/advisory/accalendar/2006/cder12543d051706.html (http://www.fda.gov/oc/advisory/accalendar/2006/cder12543d051706.html).
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May